Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Ralpha/IL-13Ralpha1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases[1][2][3].
Molekulargewicht:
(145.318 kDa)
Reinheit:
99.90
CAS Nummer:
[953400-68-5]
Target-Kategorie:
Interleukin Related
Anwendungsbeschreibung:
MCE Product type: Inhibitory Antibodies
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
